Eugene F. Douglass

The paper develops a murine model of sarcomatoid urothelial carcinoma (SUC) and finds it shares molecular and immunological features with human SUC, suggesting its use for therapeutic research.

The paper develops a mathematical model of cytokine signaling avidity, showing how receptor abundance and binding affinity influence potency across cell types and tissues.

This study compares immune cell deconvolution and cancer subtype gene signatures in TNBC, finding that immune aggregates better predict outcomes than subtype signatures.

AnchorR improves spatial alignment between H&E images and CosMx data by combining expert-defined landmarks, reducing landmark error from 121.5 m to 14.6 m.

This study compares the biology and genetic drivers of human and canine invasive urothelial carcinoma, finding shared cellular organization but distinct mutations and platform effects in organoids.

The paper develops chicken lung organoids to model avian influenza virus-host interactions and finds they contain diverse cell types and express relevant viral infection genes.

This study investigates the role of atypical p38 signaling in retinal vascular damage using a genetic knock-in mouse model, finding that blocking this pathway reduces vascular damage and pathological angiogenesis.

This paper develops a time-based drug screening platform to assess clinical utility by integrating pharmacokinetic-pharmacodynamic models and analyzing drug potency and kinetics in cancer cell lines.

This paper establishes a canine urothelial carcinoma organoid repository for comparative and translational carcinoma studies, showing genomic and transcriptomic fidelity to tissue and potential for drug testing.

This paper creates a large clinical dataset linking drug efficacy metrics to cancer outcomes and shows that exposure normalization improves the alignment between lab and clinical results.

The paper uses spatial imaging and organoid models to identify therapy-resistant CD44v9+ cancer stem cells in PDAC and show that cabozantinib may enhance immunotherapy by altering the tumor microenvironment.

This paper develops a quantitative platform to assess P-glycoprotein (Pgp) substrate specificity in cancer cells using integrated experimental and computational methods, validating results across ~150 FDA-approved oncology drugs.

The paper uses large-scale perturbation profiles to analyze drug mechanisms of action and polypharmacology across multiple tumor subtypes and tissues.

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

This study cultivates and characterizes new canine organoid lines from endometrium and pancreas, comparing them with existing lines using bulk RNA-seq to identify cell types and differences between two genetically related canines.

The paper identifies 407 Master-Regulator proteins that canalize cancer genomics into transcriptional subtypes and links genetic alterations to tumor biology through modular regulatory architectures.

The paper identifies host cell Master Regulator proteins hijacked by SARS-CoV and identifies drugs that can target these proteins to disrupt viral replication.

The paper introduces metaVIPER, an algorithm to assess protein activity in orphan tissues and single cells by integrating multiple non-tissue-matched interactomes, improving reproducibility of protein-activity signatures.